Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation

Cell Cycle

Volumn 11, Issue 17, 2012, Pages 3312-3323

  Cheng, Hairong ^a,b   Hong, Bo ^a   Zhou, Lanlan ^a   Allen, Joshua E ^a   Tai, Guihua ^b   Humphreys, Robin ^c   Dicker, David T ^a   Liu, Yingqiu Y ^a   El Deiry, Wafik S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NORTHEAST NORMAL UNIVERSITY   (China)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Colon cancer; DR4; DR5; JNK; Mitomycin C; TRAIL

Indexed keywords

BIM PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; LEXATUMUMAB; MAPATUMUMAB; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL STRAIN HCT116; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; SINGLE DRUG DOSE; UPREGULATION;

EID: 84866297291     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21670     Document Type: Article

References (36)

1. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628-33; PMID:14634624; http://dx.doi.org/10.1038/ sj.onc.1207232
2. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:3450-5; PMID:18519776; http://dx.doi.org/10.1158/1078-0432.CCR-07-1416
3. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27:6207-15; PMID:18931688; http://dx.doi.org/10.1038/onc.2008.298
4. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118:1979-90; PMID:18523647; http://dx.doi.org/10.1172/JCI34359
5. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26:3745-57; PMID:17530027; http://dx.doi.org/10.1038/sj.onc.1210374
6. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009; 647:195-206; PMID:19760076; http://dx.doi.org/10.1007/978-0-387-89520-8-14
7. Ozören N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000; 16:917-25; PMID:10762627
8. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000; 19:4604-10; PMID:11030149; http://dx.doi.org/10.1038/sj.onc.1203816
9. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-23; PMID:15118763; http://dx.doi.org/10.1038/sj.cdd.4401416
10. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008; 68:2062-4; PMID:18381408; http://dx.doi.org/10.1158/0008-5472. CAN-07-6278
11. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20:5865-77; PMID:11593392; http://dx.doi.org/10.1038/sj.onc.1204750
12. Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004; 279:35829-39; PMID:15155747; http://dx.doi.org/10.1074/jbc.M405538200
13. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12:66-80; PMID:17613437; http://dx.doi.org/10.1016/j.ccr.2007.05.006
14. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011; 3:86ra50; PMID:21653830; http://dx.doi.org/10.1126/scitranslmed.3001384
15. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992; 50:604-10; PMID:1537625; http://dx.doi.org/10.1002/ijc.2910500420
16. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-9; PMID:9563897
17. Franchi F, Barone C, Seminara P, Codacci-Pisanelli G, Codacci-Pisanelli M, Ferri GM, et al. 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. Med Oncol Tumor Pharmacother 1991; 8:75-8; PMID:1749303
18. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93:510-4; PMID:16091760; http://dx.doi.org/10.1038/sj.bjc.6602733
19. Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, et al. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs 2007; 18:709-12; PMID:17762401; http://dx.doi.org/10.1097/CAD.0b013e3280761a9d
20. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9:666-73; PMID:15120327; http://dx.doi.org/10.1016/j.ymthe.2004.02.007
21. Kumari R, Sharma A, Ajay AK, Bhat MK. Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. Mol Cancer 2009; 8:87; PMID:19845939; http://dx.doi.org/10.1186/1476-4598-8-87
22. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31; PMID:9039259; http://dx.doi.org/10.1016/S0092-8674(00)81871-1
23. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8; PMID:11561060
24. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-41; PMID:15846298; http://dx.doi.org/10.1038/sj.bjc.6602487
25. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58:1593-8; PMID:9563466
26. Hetschko H, Voss V, Seifert V, Prehn JH, Kögel D. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J 2008; 275:1925-36; PMID:18341587; http://dx.doi.org/10.1111/j. 1742-4658.2008.06351.x
27. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, et al. c-Jun NH2-terminal kinase-mediated upregulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 2004; 64:7570-8; PMID:15492284; http://dx.doi.org/10.1158/0008-5472.CAN-04-1238
28. Zhang X, Li W, Olumi AF. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res 2007; 13:7181-90; PMID:18056199; http://dx.doi.org/10.1158/1078-0432.CCR-07-1133
29. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19:5477-86; PMID:11114725; http://dx.doi.org/10.1038/sj.onc.1203936
30. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300-4; PMID:9230442; http://dx.doi.org/10.1038/40901
31. Bratton SB, Cohen GM. Death receptors leave a caspase footprint that Smacs of XIAP. Cell Death Differ 2003; 10:4-6; PMID:12655287; http://dx.doi.org/10.1038/sj.cdd.4401176
32. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-81; PMID:11875499; http://dx.doi.org/10.1038/nm0302-274
33. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17:141-3; PMID:9326928; http://dx.doi.org/10.1038/ng1097-141
34. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gélinas C, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3:409-16; PMID:11283615; http://dx.doi.org/10. 1038/35070096
35. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, et al. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279:40044-52; PMID:15226295; http://dx.doi.org/10.1074/jbc.M404541200
36. Prasad S, Yadav VR, Kannappan R, Aggarwal BB. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J Biol Chem 2011; 286:5546-57; PMID:21156789; http://dx.doi.org/10.1074/jbc.M110.183699